CellaVisions new product concept for hospital networks enters the evaluation phase
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, today announces a new product concept for networked Hospitals and associated laboratories. In March the product enters an evaluation phase at a number of European and North American laboratories. This concept gives cooperating hospitals and laboratories of all sizes the ability to digitize their manual blood tests, known as differential counts.
The new concept complements the company's current digital cell morphology products that are marketed to laboratories with large and medium-size workloads. It will allow the analysis of samples from remote laboratories connected to an existing CellaVision analyzer, promoting collaboration and resource sharing. It will be targeted at networked hospital groups and health authorities consisting of both large and small laboratories. Smaller laboratories with limited resources may now digitize their samples and have the analysis performed at a laboratory where a CellaVision instrument is located.
The concept will be evaluated by a number of hospital laboratories this spring for the company to decide and further develop the final product during the latter part of 2011. It will be demonstrated at seminars and trade fairs, including the Swedish user meeting Equalis, on March 10, and at the U.S. exhibitions ISLH and CLMA, May 6 and May 20.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses are often critical results used in the correct and timely diagnosis of illnesses such as infections and cancer. CellaVision's products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2010, net sales were 132 MSEK and sales continue to grow with the target to increase by at least 15 % per year over an economic cycle. CellaVision has its head office in Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is listed on Nasdaq OMX Stockholm, Small Cap. Read more at www.cellavision.com.